Decision: Favourable
Study Title:
A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (DIAGRID)
NREC Code:
22-NREC-CT-020
Decision:
Favourable
Study Type:
CT application
Principal Investigator:
Mr Mark Cahill
PI Institution:
Royal Victoria Eye and Ear Hospital
Sponsor:
Roche